Stability, Durability, and the “Scar-Free” Manufacturing Frontier
The clinical triumph of linear mRNA during the pandemic proved that RNA could be a “sprinter”—rapidly deployed and highly effective for transient immune activation. However, as the industry pivots in 2026 toward the chronic management of genetic and autoimmune disorders, a more durable athlete is stepping onto the track: Circular RNA (circRNA).
At Areterna, we are seeing a surge in inquiries and discussions regarding the transition from linear to circular constructs. Here is the technical breakdown of why this shift is happening and where the “bottlenecks” currently remain.
1. The Biological Advantage: Stability vs. The Exosome
The primary limitation of linear mRNA is its exposed 5’ and 3’ ends. Even with advanced capping and poly-A tail engineering, these ends are vulnerable to exonucleases like RNase R, which can degrade a linear strand within hours.
Circular RNA is a covalently closed loop. With no free ends for enzymes to “grab,” circRNA exhibits a half-life 3 to 10 times longer than linear mRNA in many cell types. In the context of the recent in vivo CAR-T breakthroughs, this durability is transformative:
- Sustained Protein Expression: circRNA can drive high-level protein production for a week or more from a single dose, compared to the 48-hour peak typically seen with linear mRNA.
- Reduced Immunogenicity: Because it lacks a 5′ cap and 3′ tail, properly purified circRNA can actually bypass certain pattern recognition receptors (PRRs), potentially allowing for higher “redosability” in chronic treatments.
2. The Manufacturing Hurdle: The Quest for “Scar-Free” Loops
While the biology of circular RNA is superior for long-term dosing, the synthesis process is significantly more complex. In 2026, the industry is grappling with two main circularization strategies:
- Ribozyme-Mediated Splicing: Using Permuted Intron-Exon (PIE) systems to self-splicing the RNA into a circle. While efficient, this can leave behind “bacterial scars” or intronic sequences that may trigger an innate immune response.
- Enzymatic Ligation: Using T4 RNA ligases to join the ends. This is “cleaner” but much harder to scale for the kilogram-level production required for global therapeutics.
The biggest challenge in 2026 isn’t just making the circle—it’s purity. Any “linear contaminants” (leftover precursors that didn’t circularize) are potent triggers for the immune system. Achieving 99%+ circularization efficiency is the new gold standard for CMC (Chemistry, Manufacturing, and Controls).
3. Divergent Evolution: Sprinters vs. Marathoners
We don’t believe circular RNA will replace linear mRNA. Instead, we are witnessing a divergence of modalities:
- Linear mRNA (The Sprinter): Will remain the platform of choice for vaccines and rapid-response oncology, where a sharp, temporary “burst” of protein is desired.
- Circular RNA (The Marathoner): Will dominate protein replacement therapies and autoimmune “resets,” where steady-state protein levels are required over long periods.
Areterna’s Market Perspective:
Regardless of the “shape” of the molecule, the industry is moving toward a “Full-Chain” Quality Requirement. Whether you are optimizing a linear construct with high-efficiency caps like Cap5011 or developing a next-gen circularization protocol, your success depends on the high quality starting materials.
At Areterna / Synthgene, we are providing the high-purity amidites and license-free capping reagents that ensure your “sprint” or your “marathon” doesn’t end in a manufacturing DNF.
References & Supplemental Reading
- Descartes-08 Investigators. mRNA-engineered CAR-T cells (Descartes-08) for the treatment of generalized Myasthenia Gravis: A randomized, double-blind, placebo-controlled phase 2b trial. Nature Medicine. 2024/2026 Update. (Note: The link provided is for the primary Phase 2 study).
- Abukhalaf AS, et al. The circular RNA landscape: Biogenesis, functions, identification pipelines, and biomedical applications. Non-coding RNA Research. 2026;11(1).
- Lemgart VT, Sawyer AJ, Kuhlman W, et al. Reprogramming CD22 CAR-T cells in vivo Using CD8-Targeted mRNA-LNPs to Treat Hematological Malignancies. Molecular Therapy. 2026;34(2).